Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma

Gynecologic Oncology

Volumn 87, Issue 3, 2002, Pages 287-294

  Leitao, Mario M ^a   Brennan, Murray F ^a   Hensley, Martee ^a   Sonoda, Yukio ^a   Hummer, Amanda ^a   Bhaskaran, Dharmendra ^b   Venkatraman, Ennapadam ^a   Alektiar, Kaled ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ABDOMEN; ADULT; AGED; ARTICLE; BONE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LEIOMYOSARCOMA; LUNG; MEDICAL RECORD; NONBIOLOGICAL MODEL; PELVIS; PREDICTION; PRIORITY JOURNAL; RECURRENT CANCER; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME; UTERUS SARCOMA; UTERUS SURGERY;

EID: 0036930778     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6840     Document Type: Article

References (33)

1. Harlow BL, Weis NS, Lofton S. The epidemiology of sarcomas of the uterus. JNC1 1986;76:399-402.
2. Zaloudek C, Norris HJ, Mesenchymal tumors of the uterus. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. New York: Springer-Verlag, 1994:487-528.
3. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr. Treatment of uterine leiomyosarcoma. Obstet Gynecol 1988;71:845-50.
4. Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, Fuller AF Jr. Uterine leiomyosarcoma and endometrial stromal sarcoma: Lymph node metastases and sites of recurrence. Gynecol Oncol 1993;50:105-9.
5. Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, Bazzurini L, Arisio R, Romagnolo C, Cristofani R. Uterine leiomyosarcoma: Analysis of treatment failures and survival. Gynecol Oncol 1996;62:25-32.
6. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, Czerwenka K, Leodolter S, Kainz C. Leiomyosarcoma of the uterus: A clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999;74:196-201.
7. Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverber S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: A Gynecologic Oncology Group Study. J Clin Oncol 1985;3:1240-5.
8. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986;12:2127-30.
9. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: Incidence, survival and mortality. Eur J Cancer 1997;33:907-11.
10. Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RJ. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-32.
11. Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Am J Obstet Gynecol 1992;166:556-9.
12. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1996;62:226-9.
13. Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler WC Jr, Creasman W, Yordan E. Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648-53.
14. Hensley ML, Maki R, Venkatraman E, and coauthors. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002;20:2824-31.
15. McCormack PM, Martini N. The changing role of surgery for pulmonary metastases. Ann Thorac Surg 1979;28:139-45.
16. Levenback C, Rubin SC, McCormack PM, Hoskins WJ, Atkinson EN, Lewis JL Jr. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 1992;45:202-5.
17. Gadd MA, Casper ES, Woodruff JM, McCormack PM, Brennan MF. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg 1993;218:705-12.
18. Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, Brennan MF. Pulmonary metastases from soft tissue sarcoma: Analysis of patterns of disease and postmetastasis survival. Ann Surg 1999;229:602-12.
19. Weiser MR, Downey RJ, Leung DH, Brennan MF. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 2000;191:184-91.
20. van Geel AN, Pastorino U, Jauch KW, Judson IR, van Coevorden F, Buesa JM, Nielsen OS, Boudinet A, Tursz T, Schmitz PI. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 1996;77:675-82.
21. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms: A clinicopathologic study of 213 cases. Am J Surg Pathol 1994;18:535-58.
22. Mazumdar M, Glassman JR. Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments. Statist Med 2000;19:113-32.
23. Currie JL, Blessing JA, Muss HB. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: A Gynecologic Oncology Group study. Gynecol Oncol 1996;61:27-30.
24. Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: A Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962-6.
25. Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: A Gynecologic Oncology Group study. Am J Clin Oncol (CCT) 2000;23:355-7.
26. Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1999;74:346-9.
27. Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1998;70:267-71.
28. Thigpen T, Blessing JA, Yordan E, Valea F, Vaccarello L. Phase II trial of etoposide in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1996;63:120-2.
29. Smith HO, Blessing JA, Vaccarello L. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2002b;84:140-4.
30. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
31. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
32. Hoskins WJ, Chi DS, Boente MP, and coauthors. State of the art surgical management of ovarian cancer. Cancer Res Ther Contr 1999;9:373-82.
33. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:532-7.